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Lung cancer rates in the US show substantial unexplained
racial variability. SEER incidence rates have been reported
higher for blacks than whites in every year since 1973, with
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 To test whether differences in smoking-related lung cancer risks in blacks and whites can ex-
plain why lung cancer incidence is greater in black males than in white males but about equal in black and





 A hospital-based case-control study was conducted between 1984 and 1998 that included
interviews with 1,710 white male and 1,321 white female cases of histologically confirmed lung cancer,
254 black male and 163 black female cases, and 8,151 controls. Relative risks were estimated via odds ra-




. We confirmed prior reports that smoking prevalence is higher but overall dosage is lower





 cigarettes per day or 37.5 pack–years), in whom ORs for blacks were considerably greater than for
whites. Long-term benefits of cessation were similar for white and black ex-smokers. Smokers of menthol




. Lung cancer risks were similar for whites and blacks with similar smoking habits, ex-
cept possibly for blacks who were very heavy smokers; this sub-group is unusual in the general population
of African American smokers. Explanations of racial disparities in lung cancer risk may need to account
for modifying factors including type of cigarette (yield, mentholation), diet, occupation, and host factors
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rate differentials between 34% and 67%. (1, 2). The preva-
lence of cigarette smoking has been considerably higher in
black than in white males since 1950. It was slightly higher
in black than in white females from 1962 until 1992, after
which the rates have been nearly equal (3–6). The seeming
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consistency between smoking and lung cancer rates is
weakened, however, by substantial differences in the num-
ber of cigarettes smoked per day (CPD). In 1991, 29.2% of
adult blacks currently smoked cigarettes compared with
25.5% of whites, but blacks smoked on average 15.0 CPD
while whites smoked 21.0 CPD. (7). Comparable differ-
ences have been reported in many other studies (5, 8–10).
Few analytic studies have addressed this anomaly. Schwartz
and Swanson (11) concluded that racial differences in inci-
dence could be “entirely explained” by smoking habits,
based on an epidemiological study of over 5500 cases diag-
nosed in Detroit area hospitals in 1984 to 1987. Neverthe-
less, their conclusion did not apply to persons under 55 years of
age, and was based on large numbers of proxy interviews,
which might have affected the precision of reported ORs.
Although smoking is the overwhelming cause of lung
cancer, other host and environmental factors may also mod-
ify risk. Modifying factors that have been studied include
diet (12, 13), genetic polymorphisms in metabolizing genes
(14–18) as well as more general familial factors (19, 20),
metabolism differences (21, 22), occupation (23), and non-
biological factors such as social class (24) and education
(25). The hypothesis that the strong preference for men-
thol flavored cigarettes among black smokers may also
partly explain risk differences has led to conflicting results
among investigators, with no association reported by our
group (26), and a positive association reported for men but
not women by Sidney et al. (27).
To better delineate smoking-related risks for lung cancer
between racial groups, it is important to make direct assess-
ments of risk in relation to smoking habits as an essential
backdrop for interpreting the impact of other risk factors,
including those observed in metabolic and molecular stud-
ies. To address these issues we examined smoking habits




Between 1984 and 1998 the American Health Foundation
performed a hospital-based case-control study in the three
major New York City cancer centers plus other hospitals in
New York, Philadelphia, Washington DC, and other US
cities (see Acknowledgments). Only incident cases were se-
lected, defined as persons diagnosed with lung cancer for
the first time during the 12 months preceding interview
(most within 2 months). All cases were confirmed by histo-
pathology. Adenocarcinomas were more common in women
(46% of cases) than in men (37%), but differed little by
race. Controls were selected from the daily admission ros-





5 y), hospital, and year of interview. Eligible control di-
agnoses excluded tobacco-related diseases such as coronary
heart disease, stroke, peripheral vascular disease, chronic
obstructive pulmonary disease, gastric ulcer, cirrhosis of the
liver, and cancers of the mouth, larynx, esophagus, bladder,
kidney, pancreas, or liver (28). Control patients for studies
of other tobacco-related cancers besides lung were being in-
terviewed at the same time as cases, so that a large control
pool of patients with non-tobacco-related diseases was
available. Approximately half of male controls had benign
or malignant diseases including benign prostatic hypertro-
phy (9%), prostate cancer (8%), colon-rectum cancer
(11%); bone and joint diseases (5%); kidney stones, ne-
phritis, and other kidney diseases (8%); abscesses (2%);
sprains, strains, and fractures including hip, and a wide vari-
ety of other non-malignant conditions requiring hospital-
ization. Forty percent of female controls had cancers which
included breast (15%), colon-rectum (7%), ovary (4%),
connective tissue (2%), and melanoma (2%); other female
controls were hospitalized for osteoarthritis (5%), fractures
including hip (5%), genital prolapse (2%), abscesses (2%)
and a wide variety of other non-malignant conditions. Af-
ter providing written informed consent using a form ap-
proved by the Institutional Review Board of each hospital,
every subject was interviewed by an AHF-trained inter-
viewer using a structured questionnaire that elicited infor-
mation on demographic variables, smoking history, and
other possible risk factors. Approximately 85% of eligible
patients who were approached agreed to be interviewed.
The 15-year accrual interval was chosen because it in-
cluded large numbers of black and white patients who were
recruited with a uniform protocol and interviewed under
similar circumstances. The present analysis overlaps and
extends earlier reports (26, 29) that included patients inter-
viewed between 1977 and 1991. This is a significant exten-
sion, since it makes use of data obtained via face to face
interviews with 11,599 patients (4192 interviewed after
1991), of whom 3448 were cases and 8151 were controls. It
includes 417 black cases, 254 of whom were male (121 in-
terviewed after 1991) and 163 female (81 interviewed after
1991).
Distributions of demographic and smoking variables
were compared using chi-square tests. Means of continuous





ratios for lung cancer were computed using unconditional
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logistic regression, with age at diagnosis entered as a con-
tinuous covariate and smoking parameters as indicator vari-
ables (30). Educational level and BMI (body mass index,
computed as weight in kg five years prior to diagnosis di-
vided by the square of height in cm) were considered to be
potentially confounding variables, based upon prior reports
from our group (31). Therefore, indicator variables for edu-
cation (3 levels) and BMI (3 levels) were included in the
logistic regression models in addition to smoking dosage.
A goal of this study was to evaluate the hypothesis that
the risk of lung cancer differs between blacks and whites for
equivalent exposure to tobacco smoke. Dosage was modeled
in current smokers using categories of CPD or cumulative
pack-years, and duration of smoking habit. Risk among ex-
smokers was estimated in relation to years since quit. Since
race is a matching variable by design, it was not appropriate
to test the regression coefficients of the main effects in
blacks versus whites for equality. Rather, a model was con-
structed that included a main effect for race (0 for white
and 1 for black) along with interaction terms for race with
each dosage variable and the covariates age, BMI, and edu-
cation to control for potential confounding. The interac-
tion of race with each of the dosage terms was then tested
against zero. This is equivalent to a Wald’s test for equality
of the race term for the same dosage variable in separate
stratified analyses for blacks or whites. A significantly non-
zero value of the regression coefficient for the race-dosage
interaction is interpreted as evidence of a black–white dif-
ference in lung cancer risk for given levels of tobacco
smoke exposure.
There was initial concern that dosages might have var-
ied during the 15-year study period. However, the average
number of cigarettes smoked per day did not change signifi-
cantly over time among men, or among black females.
White women reduced their cigarette intake by an average








0.01). In an ANOVA that included time period, sex, and
race effects, only the sex and race effects were significant,
but not time period. The distributions of CPD within each
sex-race group were also remarkably consistent over time.
Therefore, a uniform categorization of CPD was used for
the entire 15-year period, and no period adjustment was
made. Because men smoke more cigarettes per day than do
women, different groupings of CPD were used for men and





Characteristics of the patient population are shown in Ta-
ble 1. The average ages in the four sub-groups ranged be-
tween 56.9 and 61.7 years; the age distribution was




Population characteristics of lung cancer cases and hospital controls by gender
 
Male Female



























































40 2.0 3.6 4.9 4.8
 40–49 9.7 13.3 11.4 16.1  40–49 12.4 12.5 8.0 13.7
 50–59 26.3 26.6 31.1 34.1  50–59 25.7 25.4 30.1 34.9









24.2 22.7 14.7 12.3
 Mean(SD) 61.7(9.8) 59.6(10.5) 60.6(9.5) 56.9(10.3)  Mean(SD) 61.4(10.2) 60.7(10.9) 60.2(9.4) 58.0(10.2)



























12 42.9 52.9 25.8 36.9

















21.50 36.4 30.8 34.7 25.2









29.5 36.7 39.5 47.9
 Mean(SD) 26.2(3.8) 26.9(0.1) 25.0(4.0) 26.9(0.2)  Mean(SD) 24.0(4.2) 25.6(5.8) 25.5(5.3) 28.3(6.5)
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ucation level differed by disease status and race: cases had
fewer years of education than controls and blacks of either
gender in general had significantly fewer years in education
compared with whites. The mean BMI was significantly









 0.05). White females tended to be leaner
than black females, regardless of disease status.
The distribution of smoking variables is shown in Table
2. As expected, cases were far more likely than controls to
be current smokers, to have begun smoking at an earlier
age, and to have smoked for a longer period of time. Cases
who were current smokers consumed more CPD, and ex-
smokers had quit more recently compared with controls for
all sex-race groups. Cigarette consumption by females was
less intense than by males. Smoking prevalence was higher
among blacks than whites–especially in males—in both
cases and controls. Among current smokers, however,
blacks smoked significantly fewer CPD than did whites:








 0.001) and 5.8 fewer








 0.001). The lower levels of
CPD among blacks translated into substantially smaller
numbers of pack-years (18 pack–years (PY) for black male
controls and 8.7 PY for black female controls).
There was no difference between blacks and whites in
age at onset of smoking among male cases, but among fe-
male cases blacks began smoking on average 1.4 years later








 0.01). The percentage
of ex-smokers was higher for whites than for blacks, while
black ex-smokers on average had quit smoking more re-
cently than white ex-smokers had. Cessation patterns for
females were similar though less pronounced than for
males. White male cases who were ex-smokers had quit on









while a smaller difference of 1.7 year in the same direction





Distribution of smoking variables by gender and race
 
Male Female

















































% % % % % % % %
Smoking status Smoking status
 Non-smoker 3.5 29.8 2.4 25.5  Non-smoker 9.2 50.5 6.8 49.7
 Ex-smoker 49.8 49.5 33.1 36.4  Ex-smoker 37.6 33.0 30.7 23.2
 Current smoker 46.7 20.7 64.6 38.2  Current smoker 53.1 16.6 62.6 27.1
Current smoker Current smoker
 Cigarettes per day  Cigarettes per day
 1–19 10.8 25.7 26.2 62.5  1–10 9.4 28.5 24.5 50.5
 20 26.6 27.3 39.0 22.6  11–20 38.9 39.8 47.1 37.1









43.7 29.2 18.9 6.6
 Mean(SD) 32.6(15.5) 26.6(15.3) 24.4(14.1) 15.9(11.4) Mean(SD) 27.6(13.2) 20.8(12.8) 20.2(10.1) 15.0(9.2)









14 4.1 19.3 14.1 30.2
 20–37.5 16.3 24.8 32.5 33.7  14–31.5 20.3 29.5 28.3 37.5









43.1 23.6 18.2 12.5
 Mean(SD) 61.8(30.8) 47.6(27.7) 48.0(31.4) 29.6(23.0)  Mean(SD) 48.1(23.5) 34.4(22.2) 36.4(22.7) 25.7(17.2)


















54.7 36.5 49.0 32.0
 Mean(SD) 41.7(10.2) 37.0(11.6) 42.2(10.9) 34.6(12.2)  Mean(SD) 40.5(9.9) 34.8(12.3) 38.9(10.4) 35.1(11.1)
 Age at onset of smoking  Age at onset of smoking
 Mean(SD) 16.4(3.9) 17.7(5.1) 16.3(4.1) 18.4(5.8)  Mean(SD) 17.8(3.9) 20.7(7.8) 19.2(5.6) 20.8(6.8)
Cigarette preference  Cigarette preference
 Menthol cigarette 15.5 18.9 40.8 49.0  Menthol cigarette 13.5 23.7 41.6 51.8
 Non-menthol cigarette 84.5 81.1 59.2 51.0  Non-menthol cigarette 86.5 76.3 58.4 48.2
Ex-smokers Ex-smokers
 Years since quit  Years since quit
 1–10 50.9 30.9 67.9 45.0  1–5 33.5 18.6 48.0 26.5









27.8 48.9 30.0 36.1
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ORs for lung cancer in relation to overall smoking habits
and intensity are shown in Table 3. Among current smok-
ers, the OR for lung cancer among white males was compa-
rable to that among black males (21.0 vs. 18.2), and the
OR among white females was comparable to that among
black females (19.3 vs. 17.2). The ORs among ex-smokers
were similar for white and black males (7.9 and 8.1, respec-
tively). None of the black–white differences in smoking
habit ORs were statistically significant.
Classical dose-response patterns were observed in all
four sex–race combinations using either CPD or PY. The
95% confidence intervals for ORs for blacks and whites
overlapped for each specific dosage category. However, for
dosages of 20 or more CPD and 37.5 or more PY, the ORs
for black males greatly exceeded those for white males. For
example, among current smokers of 20 CPD, the OR for
black males was 34.2 (95% CI 13.3–88.3), which was
nearly 75% higher than the value of 20.0 (14.4–27.6) for




 CPD) the OR for
black males was 42.2 (15.9–111.9), nearly 50% higher than
for white males (29.8; 22.1–40.2). At the same dosage the
OR for black females (42.9; 17.0–108.4) was 28% higher
than for white females (33.6; 25.4–44.4). For cumulative
dosages above 20 PY, ORs for black males considerably ex-
ceeded those for white males, with the ORs at 37.5 PY and
above nearly twice as great in black males. The interaction








0.05). However, there were no black–white differences in
PY related ORs for females. OR estimates of risk related to
duration of smoking habit were likewise similar in blacks
and whites.
Smoking cessation effects are also shown in Table 3. Us-
ing non-smokers as the reference, ORs decreased as the
smoking cessation period expanded. Among men, the ORs
were comparable between whites and blacks, and the term




Odds ratios (adjusted for age at diagnosis, BMI and education years) for lung cancer in relation to smoking habits
 
Male Female
White Black White Black
OR(95%CI) OR(95%CI) OR(95%CI) OR(95%CI)
Smoking status Smoking status
 Non-smoker 1.0 1.0  Non-smoker 1.0 1.0
 Ex-smoker 7.9(6.0–10.3) 8.1(3.4–19.4)  Ex-smoker 6.3(5.1–7.9) 9.3(4.5–19.2)
 Current smoker 21.0(15.8–27.8) 18.2(7.6–43.4)  Current smoker 19.3(15.4–24.2) 17.2(8.7–33.7)
Current smokers Current smokers 
 Cigarettes per day  Cigarettes per day
 Non-smoker 1.0 1.0  Non-smoker 1.0 1.0
 1–19 8.4(5.9–12.1) 7.5(3.0–18.7)  1–10 6.2(4.4–8.8) 8.3(3.8–18.2)





29.8(22.1–40.2) 42.2(15.9–111.9)  21 33.6(25.4–44.4) 42.9(17.0–108.4)
 Interaction p-valuea 0.182  Interaction p-valuea 0.868
 Pack-years  Pack-years
 Non-smoker 1.0 1.0  Non-smoker 1.0 1.0
 20 6.3(4.0–9.9) 4.7(1.7–13.0)  14 3.4(2.1–5.4) 7.7(3.2–18.2)
 20.0–37.5 12.1(8.6–17.0) 16.7(6.6–41.9)  14.0–31.5 10.6(7.8–14.2) 9.7(4.5–20.9)
 37.5–55.0 15.7(11.6–21.4) 28.3(10.8–74.1)  31.5 22.7(17.9–28.8) 23.9(11.6–49.1)
 55.0 28.3(21.1–37.9) 54.7(19.4–153.9)
 Interaction p-valuea 0.035  Interaction p-valuea 0.636
Smoking duration in years Smoking duration in years
 Non-smoker 1.0 1.0  Non-smoker 1.0 1.0
 40 15.8(11.5–21.8) 16.1(6.7–45.7)  40 13.4(10.2–17.6) 14.6(6.9–30.9)
 40 25.1(18.6–33.8) 20.1(8.7–54.7)  40 24.7(19.1–32.0) 20.7(9.6–44.7)
 Interaction p-valuea 0.277  Interaction p-valuea 0.408
Ex-smokers Ex-smokers 
 Years since quit  Years since quit
 Non-smoker 1.0 1.0  Non-smoker 1.0 1.0
 1–10 14.5 (10.9–19.5) 13.7 (5.9–37.5)  1–5 10.1 (7.9–13.0) 11.0 (5.0–24.2)
 11–20 7.8 (5.8–10.6) 4.2 (1.6–12.7)  6–15 6.7 (4.8–9.4) 6.5 (2.0–20.7)
 21 3.7 (2.8–5.1) 3.9 (1.4–12.3)  16 3.4 (2.6–4.4) 7.2 (2.9–17.5)
 Interaction p-valuea 0.888  Interaction p-valuea 0.221
a p-value for term representing interaction between race and indicated dosage variable.
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tically significant. A small difference in ORs was observed
between white and black female ex-smokers with more
than 15 years of cessation. However, risk estimates among
female ex-smokers did not differ significantly between
whites and blacks.
There were only small racial differences in self-reported
depth of inhalation or the amount of each cigarette
smoked: 36% of white male and 27% white female smokers
reported that they inhaled deeply, compared with 35% of
black males and 24% of black females. Furthermore, 81% of
white males and 71% white females smoked at least two
thirds of each cigarette, compared with 81% of black males
and 75% of black females (data not shown in Tables).
Among current smokers, 45.1% of male and 46.5 of fe-
male blacks smoked menthol cigarettes, compared with
17.3% of male and 17.6% of female whites. ORs among
smokers of menthol cigarettes were practically the same as
among smokers of non-menthol cigarettes (Table 4).
DISCUSSION
Our data show few differences in lung cancer risk between
blacks and whites in both men and women. In current
smokers, relative risk estimates were similar between blacks
and whites when stratified by amount and duration of smok-
ing, and in ex-smokers by years since smoking cessation.
Higher risks were observed among black men compared
with white men for the heaviest smokers (e.g., 21 or more
CPD, 37.5 or more PY), but these differences were not sta-
tistically significant. A significant interaction was found
between dosage and race in men only (p  0.05), which
was due largely to the differences among blacks in the 55
PY category. While our data are thus consistent with differ-
ences in risk among the heaviest smokers, it should be
noted that most blacks smoke fewer than one pack per day
(32) (as do the controls in this study) and that the observed
increased risk thus occurred among a relatively small group
of black smokers. Further studies would be needed to con-
firm this possible increase in risk.
The validity of our findings depends in part on the ex-
tent of bias in this case-control design, which may be
gauged to some extent by comparison with smoking habits
in the general population. Our data are consistent with na-
tional survey data on smoking habits (32), which show a
higher prevalence of cigarette smoking in black compared
with white males, but a significantly smaller daily consump-
tion among regular smokers. The observed brand distribu-
tions in our patient population were not unusual, and the
prevalence of menthol smokers differed by only a few per-
cent from those reported in a case-control study by Carpen-
ter et al. (33). Although risks among ex-smokers did not
differ between whites and blacks, we noted substantial dif-
ferences in cessation patterns that are consistent with the
limited number of black ex-smokers. Among the controls,
white males had quit on average 4.5 years earlier than black
males (p  0.001) and white females had quit 3.0 years ear-
lier than black females (p  0.05). Ex-smokers made up a
significantly greater percentage of ever-smokers among whites
compared with blacks (71% vs. 49% for males, 67% vs.
46% for females, both p  0.001). Few population data are
available against which these cessation rates may be com-
pared, but they are consistent with patterns recently re-
ported by Gilpin and Pierce (34) who used cross-sectional
data gathered from a succession of National Health Inter-
view Surveys conducted between 1965 and 1992. They re-
ported generally lower cessation among African Americans
aged 35 to 50 years compared with whites in the same age
group.
Previous studies have shown that smoking habits are re-
lated to socioeconomic status (SES), which in turn is
strongly correlated with lung cancer risk (5). Baquet et al.
have shown that adjustment of rates for SES tends to re-
duce racial differences in risk (24). We adjusted all smok-
ing-related ORs for education. Nevertheless, there were still
large social class differences between whites and blacks as
measured by educational level. These educational differences
between lung cancer cases and controls in general are con-
sistent with many earlier reports from our group (9, 28, 29).
The lower socioeconomic status of blacks may have re-
sulted in limited access to health care and manifested as
late presentation with severely advanced disease. Among
black lung cancer patients, 81.3% presented with stage III
and IV, compared with 58.7% among white cases. If the se-
verity of lung cancer increases with the intensity of ciga-
rette smoking, an underestimate of lung cancer risk in blacks
with heavy cigarette consumption might result due to un-
dersampling of severe black lung cancer cases. However,
TABLE 4. Odds ratios for lung cancer in current smokers according to preference for menthol cigarettes adjusted for age, education (3 
levels), BMI (3 levels), and pack-years (4 levels for males and 3 levels for females)
Males Females
White Black White Black
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Non-menthol 1.00 1.00 1.00 1.00
Menthol 0.83(0.63–1.09) 1.34(0.79–2.29) 0.61(0.44–1.06) 0.79(0.41–1.54)
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within each CPD or PY category, ORs did not differ by
stage, suggesting that underestimation has not occurred.
Cigarette brands favored by black smokers might differ
in toxicity from those smoked by the majority of whites,
and it has been suggested that the greater preference for
menthol flavored cigarettes among black smokers may con-
tribute to their higher lung cancer rates (35). This prefer-
ence may be the result of racially targeted advertising by
the tobacco industry. Hoffman–Goetz et al. (36) examined
popular magazines whose readership is principally black,
and noted that in 8 years only 6 of 84 articles on cancer
specifically addressed lung cancer, while the same maga-
zines carried nearly 1500 tobacco advertisements. While
black smokers in our study were more likely to choose men-
thol than non-menthol brands (Table 2), our data provide
no evidence that menthol cigarettes per se produce greater
lung cancer risk than do non-menthol brands (Table 4).
This is consistent with a 1991 report by Kabat and Hebert
(26) based on 588 male and 456 female cases (those data
overlap the present study), as well as with the study by Car-
penter et al. (33) based on 337 cases. By contrast, Sidney et al.
(27) concluded that increased lung cancer risk was associ-
ated with menthol cigarette smoking in male but not fe-
male smokers. However, Ahiyevich (37) found no significant
differences in puff volume between black and white women
who smoked either menthol or nonmenthol cigarettes. Ex-
perimental data show no increase in NNK-induced adduct
formation in NNK-treated rats that were administered
menthol in their drinking water (NNK is a tobacco-specific
nitrosamine, which experimentally produces lung adeno-
carcinoma in rodents), further supporting our conclusion
that menthol does not play a role in risk for lung cancer.
Menthol is the only one of many flavoring agents added to
cigarettes which is used to differentiate brands from one an-
other (38, 39); little is known of possible health effects of
other additives.
We adjusted for age, education, and body mass, which
Kabat et al. (31) showed to be inversely related to lung can-
cer risk, and used BMI five years prior diagnosis to reduce
bias introduced by weight loss due to the cancer itself. Other
exposures or lifestyle situations such as occupational expo-
sures also influence lung cancer risk (40), but occupational
lung cancer studies among blacks are rare. Using data from
National Health Interview Surveys, Sterling (23) observed
that more blacks than whites held jobs with potential carci-
nogenic exposures. We recently reported elevated lung can-
cer risks among black males exposed to asbestos and coal
dust, and among black females exposed to paint and gas
fumes (41). In the present study, there were no significant
differences between blacks and whites in the proportions of
occupations known to be associated with higher lung can-
cer risk. However, the number of different occupations and
exposures was large, and there was little statistical power to
examine risk with respect to specific occupations; such in-
vestigations are more efficiently performed in cohorts of
workers occupationally exposed to lung carcinogens (42).
Metabolic mechanisms undoubtedly play a role in deter-
mining lung cancer risk. Richie and colleagues reported sig-
nificant higher levels of urinary NNAL, NNAL-Gluc, and
total NNAL in black compared with white smokers of simi-
lar CPD, and significant lower urinary NNAL-Gluc:NNAL
ratios in blacks (21). We recently measured higher levels of
both plasma and urinary cotinine, plasma thiocyanate, and
total NNAL in black compared with white smokers on a
per-cigarette basis. (43) Glucuronidation is one of the ma-
jor detoxification mechanisms for NNAL and its parent
metabolite, NNK; differences in glucuronidative capacity
may contribute to the differences in susceptibility to lung
cancer between blacks and whites. Perez-Stable et al. (22)
proposed that higher levels of cotinine per cigarette smoked
by blacks compared with whites could be explained by
slower clearance of cotinine and higher intake of nicotine
per cigarette by blacks.
Molecular epidemiologic studies have examined the role
of polymorphisms in genes coding for enzymes that activate or
detoxify mainstream tobacco smoke carcinogens like NNK,
or polycyclic aromatic hydrocarbons like benzo[a]pyrene,
but few have directly compared the risk associated with
these polymorphisms in blacks versus whites. Associations
were recently reported between the presence of the GSTM1
(0/0) genotype and increased risk for oral cancer (which
like lung cancer is also tobacco-related) in blacks but not
whites (44, 45), in a pattern that was linked to smoking
dose. As in the present study, the biggest racial difference
in risk was in heavier smokers. Although a significant asso-
ciation has not been observed for the GSTM1 null poly-
morphism and lung cancer risk in either blacks (16, 46) or
whites (47), a significant association was reported among
Japanese (48), supporting the need to examine polymor-
phic profiles for other metabolizing enzyme genes.
Supported by US Public Health Service grants CA-68384, CA-91401, and
CA-17613. We thank Marion Moore and Anna Mondora, field supervi-
sors, Vicki Liang and Preciosa Ong for computational and logistic support,
and the following interviewers: Andrea Davis, Belle Hecht, Judy Jubas,
Julian Marynczyk, Aldith Moore, Rosemary Price, Rebecca Segal, Dr. Su-
san Sheu, Matthew Skelton, and Denese Taylor. We also thank the fol-
lowing physicians and institutions for permission to enroll their patients:
Mark Pasmantier, MD, of the Division of Hematology/Oncology, Weill
Medical College, New York, NY; Roger Keresztes, MD, Division of Hema-
tology/Oncology, Cornell Comprehensive Cancer Center, New York, NY;
Elliot Strong, MD, Newton Morton, MD, Robert Ginsburg, MD, Memo-
rial Sloan-Kettering Cancer Center; Ronald H. Blum, MD, New York
University Medical Center; Edward Garrity, Jr., MD, Loyola University
Hospital, Chicago, IL; John Sharp, MD, VA Medical Center, Hines, IL;
Christine Johnson, PhD, Henry Ford Hospital, Detroit, MI; Kanti Rai,
MD, Long Island Jewish Medical Center, New Hyde Park, NY; Linga
Ragu, MD, Nassau County Medical Center, East Meadow, NY; James Col-
berg, MD, Thomas Jefferson University Hospital, Philadelphia, PA; and
Paul Stolley, MD, Hospital of the University of Pennsylvania, Philadel-
phia, PA.
AEP Vol. 13, No. 4 Stellman et al. 301
April 2003: 294–302 LUNG CANCER IN WHITES AND BLACKS
REFERENCES
1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et
al. eds. SEER Cancer Statistics Review, 1973–1997. Bethesda, MD:
National Cancer Institute; 2000.
2. Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma
incidence trends. Cancer. 1996;77:2464–2470.
3. Shopland DR, Burns DM, eds. Changes in cigarette-related disease risks
and their implication for prevention and control. Smoking and tobacco
control monographs No. 8. NIH publication no. 97–4213. Bethesda, MD:
National Institutes of Health, National Cancer Institute; 1997.
4. US Department of Health and Human Services. Tobacco Use Among
US Racial/Ethnic Minority Groups—African Americans, American
Indians and Alaska Natives, Asian Americans and Pacific Islanders,
and Hispanics: A Report of the Surgeon General. Atlanta: USDHHS
Office of Smoking and Health; 1998.
5. Stellman SD, Resnicow K. Tobacco smoking, cancer and social class.
In: Kogevinas M, Pearce N, Susser M, Boffetta P, eds. [IARC Scien-
tific Publications, No. 138.] Social Inequalities and Cancer. Lyon: In-
ternational Agency for Research on Cancer; 1997:229–249.
6. Anonymous. From the Centers for Disease Control. Trends in lung
cancer incidence and mortality–United States, 1980–1987. JAMA.
1991;265:448.
7. Centers for Disease Control. Cigarette smoking among adults—
United States, 1991. Morb Mortal Wkly Rep. 1993;42:230–233.
8. Satariano WA, Swanson GM. Racial differences in cancer incidence:
the significance of age-specific patterns. Cancer. 1988;62:2640–2653.
9. Kabat GC, Morabia A, Wynder EL. Comparison of smoking habits of
blacks and whites in a case-control study. Am J Public Health.
1991;81:1483–1486.
10. Zang EA, Wynder EL. Smoking trends in the United States between
1969 and 1995 based on patients hospitalized with non-smoking re-
lated diseases. Prev Med. 1998;27:854–861.
11. Schwartz AG, Swanson GM. Lung carcinoma in African Americans
and whites. A population-based study in metropolitan Detroit, Michi-
gan. Cancer. 1997;79:45–52.
12. Koo LC. Diet and lung cancer 20 years later: more questions than
answers? Int J Cancer 1997;(suppl 10):22–29.
13. Pillow PC, Hursting SD, Duphorne CM, Jiang H, Honn SE, Chang S,
et al. Case-control assessment of diet and lung cancer risk in African
Americans and Mexican Americans. Nutr Cancer. 1997;29:169–173.
14. London SJ, Daly AK, Leathart JB, Navidi WC, Carpenter CC, Idle
JR. Genetic polymorphism of CYP2D6 and lung cancer risk in Afri-
can-Americans and Caucasians in Los Angeles County. Carcinogene-
sis. 1997;18:1203–1214.
15. London SJ, Daly AK, Cooper J, Carpenter CL, Navidi WC, Ding L, et
al. Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymor-
phism among African Americans and Caucasians in Los Angeles
County. Pharmacogenetics. 1996;6:151–158.
16. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR.
Polymorphism of glutathione S-transferase M1 and lung cancer risk
among African Americans and Caucasians in Los Angeles County,
California. J Natl Cancer Inst. 1995;87:1246–1253.
17. London SJ, Daly AK, Fairbrother KS, Holmes C, Carpenter CL, Na-
vidi WC, et al. Lung cancer risk in African Americans in relation to a
race-specific CYP1A1 polymorphism. Cancer Res. 1995;55:6035–6037.
18. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR. Lung cancer
risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism
among African Americans and Caucasians in Los Angeles County,
California. Pharmacogenetics. 1996;6:527–533.
19. Bondy ML, Spitz MR, Halabi S, Fueger JJ, Schantz SP, Sample D,
et al. Association between family history of cancer and mutagen sensi-
tivity in upper aerodigestive tract cancer patients. Cancer Epidemiol
Biomarkers Prev. 1993;2:103–106.
20. Wu X, Dave BJ, Jiang H, Pathak S, Spitz MR. Lung carcinoma pa-
tients with a family history of cancer and lymphocyte primary chro-
mosome 9 aberrations. Cancer. 1997;79:1527–1532.
21. Richie JP Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, Hecht
SS. Differences in the urinary metabolites of the tobacco-specific
lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in
black and white smokers. Cancer Epidemiol Biomarkers Prev. 1997;6:
783–790.
22. Perez-Stable EJ, Herrera B, Jacob P 3rd, Benowitz NL. Nicotine me-
tabolism and intake in black and white smokers. JAMA. 1998; 280:
152–156.
23. Sterling TD, Weinkam JJ. Comparison of smoking-related risk factors
among black and white males. Amer J Indust Med. 1989;15:319–333.
24. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors
and cancer incidence among blacks and whites. J Natl Cancer Inst.
1991;83:551–557.
25. Wagenknecht LE, Perkins LL, Cutter GR, Sidney S, Burke GL, Man-
olio TA, et al. Cigarette smoking is strongly related to educational
status: the CARDIA study. Prev Med. 1990;19:158–169.
26. Kabat GC, Hebert JR. Use of mentholated cigarettes and lung cancer
risk. Cancer Res. 1991;51:6510–6513.
27. Sidney S, Tekawa IS, Friedman GD, Sadler MC, Tashkin DP. Men-
tholated cigarette use and lung cancer. Arch Intern Med. 1995;155:
727–732.
28. Wynder EL, Stellman SD. Comparative epidemiology of tobacco-
related cancers. Cancer Res. 1977;37:4608–4622.
29. Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differ-
ences in lung cancer risk associated with cigarette smoking. Int J Epi-
demiol. 1993;22:592–599.
30. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. I.
The Analysis of Case-Control Studies. (IARC Scientific Publications,
No. 32.) Lyon: International Agency for Research on Cancer; 1980.
31. Kabat GC, Wynder EL. Body mass index and lung cancer risk. Am J
Epidemiol. 1992;135:769–774.
32. Giovino GA, Schooley MW, Zhu BP, Chrisomon JH, Tomar SL, Ped-
dicord JP, et al. Surveillance for selected tobacco-use behaviors —
United States, 1900–1994. MMWR 1994;43:1–43.
33. Carpenter CL, Jarvik ME, Morgenstern H, McCarthy WJ, London SJ.
Mentholated cigarette smoking and lung-cancer risk. Ann Epidemiol.
1999;9:114–120.
34. Gilpin EA, Pierce JP. Demographic patterns in the incidence of smok-
ing cessation: United States 1950–1990. Ann Epidemiol. 2002; 12: 141–150.
35. Richardson TL. African-American smokers and cancers of the lung
and of the upper respiratory and digestive tracts. Is menthol part of the
puzzle? West J Med. 1997;166:189–194.
36. Hoffman-Goetz L, Gerlach KK, Marino C, Mills SL. Cancer coverage
and tobacco advertising in African-American women’s popular maga-
zines. J Community Health. 1997;22:261–270.
37. Ahijevych K, Gillespie J, Demirci M, Jagadeesh J. Menthol and non-
menthol cigarettes and smoke exposure in black and white women.
Pharmacol Biochem Behav. 1996;53:355–360.
38. Caskey NH, Jarvik ME, McCarthy WJ, Rosenblatt MR, Gross TM,
Carpenter CL. Rapid smoking of menthol and nonmenthol cigarettes
by black and white smokers. Pharmacol Biochem Behav. 1993;46:
259–263.
39. Cummings MK, Giovino G, Mendicino AJ. Cigarette advertising and
Black-White differences in brand preferences. Public Health Rep.
1987;102:698–701.
40. Stellman JM, Stellman SD. Cancer and the workplace. CA Cancer J
Clin. 1996;46:70–92.
41. Muscat JE, Stellman SD, Richie JP Jr, Wynder EL. Lung cancer risk
and workplace exposures in black men and women. Environ Res.
1998;76:78–84.
302 Stellman et al. AEP Vol. 13, No. 4
LUNG CANCER IN WHITES AND BLACKS April 2003: 294–302
42. Stellman SD, Demers PA, Colin D, Boffetta P. Cancer mortality and
wood dust exposure among American Cancer Society Cancer Preven-
tion Study-II (CPS-II) participants. Amer J Indust Med. 1998;34:
229–237.
43. Muscat JE, Djordjevic MV, Day-Stephenson G, Cox J, Stellman SD,
Richie JP Jr. Differences in exposure to tobacco smoke constituents in
healthy black and white smokers. Proc Amer Assoc Cancer Res.
2001;42:889.
44. Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stern JC, et
al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk.
Cancer Epidemiol Biomarkers Prev. 1997;6:791–797.
45. Park JY, Muscat JE, Schantz SP, Stern JC, Lazarus P. Association
between GSTM polymorphisms and risk for oral cancer between
African-Americans and Caucasians. Pharmacogenetics. 2000;10:
123–131.
46. Kelsey KT, Spitz MR, Zuo ZF, Wiencke JK. Polymorphisms in the
glutathione S-transferase class mu and theta genes interact and in-
crease susceptibility to lung cancer in minority populations (Texas,
United States). Cancer Causes Control. 1997;8:554–559.
47. Houlston RS. Glutathione S-transferase M1 status and lung cancer
risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 1999;8:
675–682.
48. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the
CYP1A1 and glutathione S-transferase genes associated with sus-
ceptibility to lung cancer in relation to cigarette dose in a Japanese
population. Cancer Res. 1993;53:2994–2999.
